L'age M, Arasteh K
II. Innere Abteilung des Auguste-Viktoria-Krankenhauses, Berlin-Schöneberg.
Med Klin (Munich). 1990 Apr;85 Suppl 2:255-7.
The incidence of systemic side effects under aerosolized pentamidine treatment or prophylaxis for pneumocystis carinii pneumonia is low when compared to intravenous application. Erythema, hypotension, hypoglycemia, renal failure are infrequently seen. Local side effects--cough, bronchial spasm, metallic taste--are frequent complications of aerosolized pentamidine treatment. Cystic lung disease, pneumothorax, and atypical pneumonia may be a late sequelae of pneumocystis carinii pneumonia, and not a primary effect of pentamidine. Poor apical ventilation due to suboptimal inhalation technique etc. and decreased deposition of pentamidine in these areas may be of some consequence for the development of these unusual complications. Extrapulmonary pneumocystis infections under preventive pentamidine aerosol treatment for pneumocystis carinii pneumonia have been seen in single cases, a causal relationship to pentamidine application is not yet established.
与静脉注射相比，雾化喷他脒治疗或预防卡氏肺孢子虫肺炎时全身副作用的发生率较低。红斑、低血压、低血糖、肾衰竭很少见。局部副作用——咳嗽、支气管痉挛、金属味——是雾化喷他脒治疗的常见并发症。囊性肺病、气胸和非典型肺炎可能是卡氏肺孢子虫肺炎的晚期后遗症，而非喷他脒的主要作用。吸入技术欠佳等导致肺尖通气不良以及喷他脒在这些区域的沉积减少，可能对这些不寻常并发症的发生有一定影响。在预防卡氏肺孢子虫肺炎的雾化喷他脒治疗中，曾有个别病例出现肺外肺孢子虫感染，与喷他脒应用的因果关系尚未确立。
